Print

A Registry of People with Triple Negative Breast Cancer and/or an ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53 Genetic Mutation

https://www.facingourrisk.org/research-clinical-trials/study/403 /a-registry-of-people-with-triple-negative-breast-cancer-andor-an-atm-bard1-brca1-brca2-brip1-cdh1-chek2-epcam-mlh1-msh2-msh6-nf1-palb2-pten-rad51c-rad51d-stk11-tp53-genetic-mutation

Clinicaltrials.gov identifier:
NCT02302742 (https://clinicaltrials.gov/show/NCT02302742)

Surveys, Registries, Interviews
Registry study for TNBC and hereditary breast and ovarian cancer mutations

Study Contact Information:

For additional information, please contact:

Name: Joshua Staley
Phone Number: 913-588-8548
Email: [email protected]

Or the contact listed for the study location closest to you.

About the Study

This registry is collecting cancer-related information from people with triple-negative breast cancer and from people with inherited mutations linked to breast and ovarian cancer, such as an ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53 genetic mutation. The goal is to better understand how these genetic changes may be related to cancer outcomes in triple-negative breast cancer.

What the Study Involves 

There are 2 groups in this study:

  1. People with triple-negative breast cancer
  2. People with an inherited mutation in a gene related to breast and ovarian cancer

Participants will be asked to provide a blood sample as part of this study and will be followed for 10 years.

This Study is Open To:

People of any age, who meet one of the following criteria:

  1. Triple-negative breast cancer (ER-negative, PR-negative, HER2-negative)
    1. Diagnosed within the past 5 years
    2. Any stage (I-IV)
    3. Any age at diagnosis
    4. Genetic testing status does not affect eligibility
  2. People with an inherited genetic mutation in a gene related to breast and ovarian cancer
    1. Pathogenic or Uncertain (VUS) changes in genes such as: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53
    2. People can join regardless of their personal cancer history – both previvors and those who have been diagnosed with cancer are welcome

This Study is Not Open To:

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.